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Differential Influences of the Aryl Hydrocarbon Receptor
on Th17 Mediated Responses in vitro and in vivo
Joa˜o H. Duarte, Paola Di Meglio, Keiji Hirota¤, Helena Ahlfors, Brigitta Stockinger*
Division of Molecular Immunology, MRC National Institute for Medical Research, London, United Kingdom
Abstract
The aryl hydrocarbon receptor (AhR) has been attributed with anti-inflammatory effects in the development of pathological
immune responses leading to experimental autoimmune encephalomyelitis (EAE) via the induction of regulatory T cells. In
agreement with previously published findings, we find that TCDD administration confers protection from EAE, however, this
immuno-modulatory effect was not the consequence of de novo Treg generation, but the inhibition of Th17 cell
differentiation. Systemic application of FICZ at the time of immunization also reduced EAE pathology albeit to a lesser
degree than TCDD. In vitro Th17 differentiation in the presence of AhR agonists, including TCDD, promoted IL-17 and IL-22
expression, but did not induce Treg differentiation. AhR affinity influenced the amounts of IL-17 and IL-22 protein that was
secreted by Th17 cells, but did not seem to affect susceptibility to EAE in vivo. Making use of conditional AhR-deficient mice,
we show that the anti-inflammatory effect of TCDD depends on AhR activation in both T cells and dendritic cells, further
emphasising the ability of TCDD to interfere with T effector cell differentiation in vivo. The dichotomy between the in vivo
and in vitro effects of AhR reveals the complexity of the AhR pathway, which has the capacity of affecting different AhR-
expressing cell types involved in mounting immune responses, thus participating in defining their outcome.
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Introduction
CD4+ T lymphocytes expressing interleukin (IL)-17 (Th17 cells)
constitute a distinct subset of effector T cells with a specific
transcriptional program, defined by the lineage determining
factors RORct and RORa[1,2]. Despite their crucial contribution
to protection against extracellular pathogens [3], Th17 cells have
been implicated in the immunopathology of a range of inflam-
matory diseases such as psoriasis [4], rheumatoid arthritis [5] and
multiple sclerosis [6,7].
The ligand-dependent transcription factor aryl hydrocarbon
receptor (AhR), best known for mediating the transcriptional
response to xenobiotics such as 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) [8], was shown to enhance the Th17 develop-
mental program [9] and to induce the expression of the cytokine
IL-22 in Th17 cells [10]. Th17 cells play a crucial role in the
pathogenesis of experimental autoimmune encephalomyelitis
(EAE), a murine model of multiple sclerosis (MS), where invasion
of the central nervous system (CNS) by myelin-specific Th17 cells
leads to neuronal degeneration and progressive limb paralysis [11].
Autoimmune diseases such as MS are multifactorial and, in
addition to genetic factors, environmental factors influence the
initiation and progression of disease. Thus, the involvement of
AhR agonists in shaping the course of autoimmune pathology
could constitute a link to environmental factors that influence
autoimmune disease. While AhR-deficient mice developed a much
milder form of EAE with many mice protected from onset of
disease altogether [10], the application of AhR agonists caused
differential effects. The local administration of the tryptophan
metabolite 6-formylindolo(3,2-b)carbazole (FICZ), an endogenous
AhR agonist [12], exacerbated disease [10], while systemic
administration of TCDD had the same ameliorating effect on
disease progression as AhR-deficiency [9]. This led to the
suggestion that AhR exerts its effects on immune responses in a
ligand-dependent manner. AhR activation has been reported to
have an overall anti-inflammatory effect, which was linked to
induction of regulatory T (Treg) cells [9,13], promotion of the
differentiation of IL-10-expressing Tr1 cells [14,15], and induction
of a tolerogenic phenotype in dendritic cells (DC) [16–18].
Here we show that AhR ligands such as TCDD and FICZ both
upregulate the Th17 program in vitro with the magnitude of
response depending on AhR affinity. Their effects in vivo depend
on timing and mode of application, suggesting that the mode of
action of these two AhR ligands in vivo is more likely to be shaped
by their differential susceptibility to metabolic feedback control.
TCDD is the most stable of all xenobiotic AhR ligands [19],
whereas FICZ is rapidly metabolised by AhR induced cytochrome
P450 enzymes [20], thus causing only transient AhR signalling.
Furthermore, we show that limiting AhR deficiency to defined
haematopoietic cell types results in partial alleviation of the
suppressive effect of TCDD on EAE development.
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Materials and Methods
Ethics Statement
All animal experiments were approved by the local Ethical
Review panel at NIMR in accordance with the Institutional
Committees on Animal Welfare of the UK Home
Office (the Home Office Animals Scientific Procedures Act,
1986)
Mice
C57Bl/6, Rag1.Cre [21], CD11c.Cre (Jackson stock 008068
B6.Cg-Tg(Itgax-cre)1-1Reiz/J [22], AhRfl/fl (Jackson Stock 006203
B6.129(FVB-Ahrtm3.1Bra/J), AhR2/2 (B6 BRA AHRKO) [23] and
Foxp3eGFP reporter mice [24] were bred in the NIMR animal
facility under specified pathogen free conditions.
EAE induction
Mice were injected at the base of tail with 100 ml emulsion of
IFA containing 250 mg MOG peptide fragment 35–55 and 250 mg
Mycobacterium tuberculosis strain H37Ra, followed by 200ng Bordetella
pertussis (Calbiochem) i.p. on the day of immunization and two
days later. Clinical assessment of EAE was performed daily and
clinical scores were assessed according to the following criteria: 0
= unaffected, 1 = flaccid tail, 2 = impaired righting reflex and/
or gait, 3 = partial hind limb paralysis, 4 = total hind limb
paralysis, 5 = total hind limb paralysis with partial fore limb
paralysis. 1 mg/mouse TCDD or 200 mg/mouse FICZ (or olive oil
as vehicle control) were given as a single i.p. dose of as described
[9] either on the day of MOG/CFA immunization or 5–7 days
later.
Analysis of draining lymph nodes and spinal cord
infiltrating cells
At the time points depicted, single cell suspensions were
obtained from paraaortic lymph nodes or from the spinal cord
by mechanical dissociation. Anti-abTCR (H57-597), anti-CD4
(GK1.5), anti-CD25 (PC61.5), anti-CD44 (IM7), anti-Foxp3 (FJK-
16s), anti-IFN-c (XMG1.2), and anti-IL-17A (TC11-18H10.1)
were obtained from eBioSciences. Anti-IL-1R1 (JAMA-147) and
anti-CCR6 (140706) were purchased from Biolegend. Anti-IL-22
(MH22B2) was purified from culture supernatant of the hybrid-
oma and labelled in our laboratory [10]. For intracellular cytokine
staining cells were stimulated for 4 h with PdBU (500 ng/ml) and
ionomycin (500 ng/ml) in the presence of brefeldin A (1 mg/ml)
and Fc block (BD), while simultaneously stained for surface
markers (CD4, TCRb), then fixed with 3.8% PFA, permeabilized
with 0.1% NP-40 and stained for IL-17A and IFN-c (Biolegend).
Intranuclear staining for Foxp3 was performed using the Foxp3
Staining Kit (eBioscience) according to the manufacturer’s
instructions. Cells were acquired on a FACSCanto II (BD) and
data analysis was performed using FlowJo (TreeStar) software.
In vitro T cell differentiation and intracellular staining
Naı¨ve CD4 T cells (CD4+, CD252, CD442) were isolated by
FACS sorting using a MoFlo XDP (Beckman Coulter) and
cultured in Iscove’s modified Dulbecco medium (IMDM, Sigma)
supplemented with 261023M L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, 561025 M b-mercaptoethanol and 5%
fetal calf serum. Th17 and Treg cells were differentiated on plates
coated with 2 mg/ml anti-CD3 + 5 mg/ml anti-CD28, with a
cytokine cocktail of 50 ng/ml IL-6, 1 ng/ml TGFband1d ng/ml
IL-1 (Th17) and 5 ng/ml TGFb (Treg). Intracellular cytokines
were measured as described above on day 4 after initiation of
cultures. AhR ligands were tested on T cells in vitro in a range of
concentrations to determine maximum effect without toxicity, and
used at optimal concentrations in Th17 or Treg differentiation
assays: TCDD was used at 100 nM and FICZ, ITE, 3MC and b-
NF at 0.5 mM. For co-culture experiments, bone marrow derived
DC (BMDC) were obtained by stimulating bone marrow cells with
recombinant GM-CSF for 7 days and cultured with naı¨ve T cells
at a ration of 5:1 (T cells to DC). For proliferation analysis of Th17
cultures, T cells were stained with Cell Trace Violet (Invitrogen)
for 20mins prior to culture; division index (average number of cell
divisions each cell has undergone), replication index (fold-
expansion of dividing cells) and percentage of divided cells were
calculated using Proliferation platform with FlowJo software
(Treestar).
Determination of cytokines levels
IL-17A, IL-22 and IL-10 cytokine levels in cell supernatants
were assayed using the Milliplex MAP Mouse Th17 Magnetic
Bead Panel (Merck Millipore) according to the manufactures’
instructions, and acquired on a Bio-Plex 200 flow-based sorting
and detection analyser (Bio Rad).
RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNA was obtained using TRIzol (Life Technologies)
according to the manufacturers’ instructions and reverse tran-
scribed into cDNA. ahr, foxp3 and il1r1
mRNA expression was assessed by real-time quantitative PCR
using Taqman assays (Life Technologies) according to the
manufacturers’ instructions. For each sample, mRNA abundance
was normalized to the amount of mouse hprt. Data analysis was
performed using the DCt method: results are expressed either as
fold change or as relative mRNA levels.
Statistical Analysis
Statistical analysis was performed using Prism version 5.0
(GraphPad Software). For EAE clinical score comparisons, values
are expressed as the mean 6 S.E.M. of n animals and data shown
are representative of at least 2 independent experiments.
Comparisons were calculated by two-way ANOVA test, followed
by Dunnet post-test for multiple comparisons. Cell numbers and
frequencies were compared by upaired t test or one-way ANOVA
followed by Dunnet post-test for multiple comparisons. The level
of statistically significant difference was defined as p # 0.05.
Results
TCDD inhibits the establishment and progression of
experimental autoimmune encephalomyelitis
The mouse model experimental EAE recapitulates some aspects
of the progressive paralysis observed in MS patients. Following
administration of Myelin Oligodendrocyte Glycoprotein Peptide
(MOG) peptide emulsified in complete Freund’s adjuvant, myelin-
reactive Th17 cells will undergo activation in lymph nodes and
cross the blood-brain barrier, initiating an inflammatory cascade
in the central nervous system which will lead to neuronal
degeneration and gradual limb paralysis. In agreement with
published data [9], administration of TCDD at the time of
immunization systemically reduced disease incidence from 100%
to 47%, and decreased the severity of disease in mice that show
clinical manifestations of EAE (Fig. 1A). We and others have
previously shown that local administration of FICZ (combined in
the emulsion with antigen and CFA) exacerbates EAE [9,10].
However, systemic administration of FICZ by intraperitoneal
injection resulted in partial inhibition of EAE midway to that seen
AhR Effects on Th17 Responses
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following administration of TCDD (Fig. 1A). To better charac-
terize the clinical phenotype observed in immunized mice
following systemic AhR activation, we assessed the number of T
cells recovered from draining lymph nodes and spinal cord. Mice
that had received TCDD showed significantly decreased numbers
of Th17 cells in draining lymph nodes on day 6 after
immunization, whereas at this time point there was no change
in the number of Treg, albeit their frequency was slightly increased
as reported previously [9] (Fig. 1B). In the spinal cord of TCDD-
treated immunized mice the overall number of all infiltrating T
cells, including Treg was dramatically decreased on day 15 after
immunization (Fig. 1C). Following EAE induction in the presence
of i.p.-administered FICZ, there were no significant changes
visible in the draining lymph nodes (Fig. 1D), whereas the spinal
cord showed an intermediate phenotype with respect to the vehicle
control (Fig. 1E).
These observations imply that chronic activation of AhR
prevents Th17 mediated immune inflammation in the central
nervous system. Thus, the consequences of AhR activation during
Th17-mediated immune responses appear to be dependent on the
route of administration rather than the type of ligand.
Immunosuppressive effect of TCDD depends on the
timing of administration
As shown above, administration of TCDD simultaneously with
the immunogen inhibited EAE development, and reduced the
proportion and absolute numbers of IL-17 as well as IFN-c-
secreting CD4 T cells. In contrast, delaying administration of
TCDD to 5 (data not shown) or 7 days after immunization allowed
normal EAE development similarly to what was observed in the
control group that did not receive TCDD (Fig. 2A). The number
of Th17 cells recovered from the draining lymph nodes at day 9
after immunization in delayed TCDD administration was similar
to that seen in vehicle immunized mice, and in strong contrast to
the reduced numbers seen when TCDD was given concomitant
with the immunization (Fig. 2B).
Whereas the number of Treg on day 6 after immunization was
not altered with TCDD administration (Fig. 1B), when analysed
on day 9 post immunization Treg numbers (but not percentages,
data not shown) were partially reduced when TCDD was given
either simultaneously with the immunization or 7 days after
immunization (Fig. 2B). This suggests that AhR activation affects
an early step in Th17 cell differentiation, which is no longer crucial
once T cells are activated.
AhR activation by TCDD in vitro promotes Th17
differentiation but not iTreg generation
It has been suggested previously [9,13,25] that TCDD induces
Treg, whereas the endogenous AhR ligand FICZ promotes (but
does not induce) Th17 differentiation. A prerequisite for an
influence of AhR on differentiation of Treg is that it is expressed
prior to differentiation. Expression of ahr measured by qPCR was
not detectable in non-polarised activated T cells, whereas it was
high in in vitro differentiated Th17 cells and in ex vivo isolated Th17
cells, but an order of magnitude lower in Treg, whether in vitro
generated iTreg or ex vivo isolated nTreg. Cyp1a1 expression was
only detectable upon AhR stimulation under Th17 cell conditions
as previously documented [10,26] (Fig. 3A). Previous studies also
detected AhR expression in Tr1 cells (15). Upon culture of FACS
sorted GFP-ve naı¨ve CD4 T cells from Foxp3 reporter mice in the
presence of TCDD and/or TGFb there was no foxp3 induction
above background with TCDD, either measured by expression of
foxp3 in qPCR (Fig. 3B) or by FACS analysis for Foxp3-GFP
reporting (Fig. 3C). In cultures with TGFb-induced foxp3,
addition of TCDD did not increase TGFb-mediated induction
of foxp3, making it unlikely that there is a major AhR mediated
effect on iTreg generation. This is in concordance with our
previous demonstration that naı¨ve CD4 T cells do not express
AhR [10]. In contrast, we observed that Th17 cell differentiation
and the induction of IL-22 in vitro was substantially increased in the
presence of a wide range of AhR ligands, including TCDD (Fig.
3D), showing that AhR activation has a ligand independent effect
on Th17 promotion and IL-22 induction in vitro. There was no
influence of TCDD on cell division during Th17 cell culture in vitro
(Fig. 3E). Furthermore, Th17 cell differentiation in the presence
of antigen presenting cells also showed similar enhancement by
TCDD and FICZ, whereas there was no influence on Foxp3
induction under conditions that allow Treg differentiation (TGFb
without LPS) (Fig. 3F).
AhR controls IL-1 receptor type 1 on Th17 cells
In a search for molecules controlled by AhR activation in Th17
cells, we had performed microarray analyses between WT and
AhR-deficient Th17 cells in the presence of FICZ (data not
shown). Amongst downstream targets upregulated by AhR
activation such as IL-22, CYP1A1, CYP1B1 and the AhR
repressor (AhRR), we identified the IL-1 receptor type 1 gene
(Il1r1) as overexpressed in FICZ stimulated WT Th17 cells.
Expression of the Il1r1 is highly important for the effector function
of Th17 cells as Il1r1-deficient animals fail to develop functional
Th17 cell responses and consequently do not succumb to
pathology in EAE [27,28]. In order to validate the specific
expression of Il1r1, Th0, Th1, Th2, iTreg, and Th17 cells were
differentiated from naı¨ve WT or AhR-deficient CD4 T cells and
Il1r1 mRNA expression was assessed by quantitative RT-PCR.
Il1r1 mRNA expression was barely detectable in CD4 T cell
subsets other than WT Th17 cells, which robustly increased Il1r1
in the presence of FICZ (Fig. 4A), whereas AhR-deficient Th17
cells showed impaired Il1r1 mRNA expression. Il1r1 mRNA levels
increased during Th17 differentiation (Fig. 4B). Co-staining of
surface IL-1R1 and intracellular IL-17 confirmed the reduced
expression of IL-1R1 on AhR-deficient Th17 cells. Activation of
AhR increased Th17 polarization and IL-1R1 expression in WT,
but not AhR-deficient CD4 T cells (Fig. 4C).
Similar Th17 differentiation in T cells bearing different
AhR isoforms and stimulated with different AhR ligands.
A low affinity isoform of AhR (AhRd), which is the result of an
Ala to Val change at residue 375 [29], was reported to have 10
fold lower affinity for TCDD [29] and we therefore compared the
effect of different AhR ligands on differentiation of Th17 cells
from B6 (AhRb1) and congenic B6 mice expressing AhRd. Culture
of sorted naı¨ve CD4 T cells under Th17 cell inducing conditions in
the presence or absence of four different AhR agonists, in
concentrations that were determined to induce the maximum
polarization while averting any toxicity effects (data not shown),
showed little difference between AhRb1 or AhRd expressing strains
with respect to induction of IL-17 and IL-22 (Fig. 5A). On the
level of mRNA expression for Th17 cytokines there was a
tendency of lower expression in AhRd Th17 cells, which reached
significance for TCDD and FICZ (Fig. 5B) and the effect was
more pronounced on protein level where TCDD, FICZ and 3-
MC all induced less IL-17 and IL-22 protein in Th17 cells from
AhRd compared with AhRb mice (Fig. 5C). However, induction
of EAE resulted in similar onset and level of pathology in AhRd
and AhRb expressing mice (Fig. 5D).
AhR Effects on Th17 Responses
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Deletion of AhR in either DCs or T/B cells causes
reduction in EAE pathology following TCDD
administration
Next we sought to define the cell type targeted for the
immunosuppressive effect of systemic AhR activation in vivo. For
this we made use of conditional AhR-deficient mouse strains
(AhRfl/fl) [30] and crossed them with mice expressing Cre
recombinase under control of either the promoter for CD11c
[22] or the promoter for recombination activating gene 1 (Rag1)
[21], deleting AhR either in CD11c-expressing cell types (DCs,
some macrophages and a proportion of NK cells) or in all T and B
cells respectively (Fig. 6A,D). It should be noted that the AhR on
the remaining cell types in such mice is of the low affinity AhRd
Figure 1. TCDD and FICZ administration inhibit EAE establishment and dampen T cell expansion and infiltration of the central
nervous system. A) Clinical scores of mice immunized with MOG/CFA which received either vehicle (filled circles), TCDD (inverted triangles) or FICZ
(filled squares) i.p. at the time of immunization; table showing incidence, mean day of onset and mean maximum score of disease. Data shown as
mean 6 SEM are representative of 2 independent experiments, ***p,0.001, **p,0.01 in two-way ANOVA followed by Dunnet post-test. B) Number
of IL-17A+, and number and frequency of Foxp3+ T cells recovered from draining lymph nodes on day 6 post immunization in mice that received
TCDD. Data shown as mean 6 SEM are representative of 2 independent experiments. *p,0.05 in Student’s T test. C) Number of IL-17A+, IFN-c+ and
Foxp3+ T cells, and frequency of Foxp3+ T cells recovered from the spinal cord on day 15 post immunization in mice that received TCDD. Data shown
as mean 6 SEM are representative of 2 independent experiments. *p,0.05 in Student’s T test. D) Number of IL-17A+, and number and frequency of
Foxp3+ T cells recovered from draining lymph nodes on day 6 post immunization in the presence of FICZ. E) Number of IL-17A+, IFN-c+ and Foxp3+ T
cells, and frequency of Foxp3+ T cells recovered from the spinal cord on day 15 post immunization in mice that received FICZ. Data shown as mean6
SEM are representative of 2 independent experiments.
doi:10.1371/journal.pone.0079819.g001
AhR Effects on Th17 Responses
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type, as the AhRfl/fl mice were generated on an AhRd background.
We induced EAE in mice lacking AhR expressing in all Rag1-
expressing cell types and controls (Rag1Cre+ AhRfl/fl R26R eYFP
and Rag1Cre- AhRfl/fl R26R eYFP). As shown in Fig. 5C, EAE
onset and progression was similar in controls and experimental
groups immunized with MOG/CFA and injected with vehicle
(olive oil). However, the absence of AhR in T and B cells led to
onset of EAE after treatment with TCDD with the same incidence
as that seen in controls, but with the mean maximal scores reduced
compared with control values (Fig. 6B,C). A similar effect was
seen in mice with deletion of AhR in CD11c-expressing cells (Fig.
6E,F). Our findings indicate that EAE progression per se was not
affected by the absence of AhR from T and B cells, or from
dendritic cells/macrophages, but that the immunosuppressive
effect of TCDD was partially lost when either of these cell types
was AhR-deficient. These results suggest that the immunosup-
pressive effect of systemic TCDD administration is exerted
through AhR expression on T cells as well as antigen presenting
cells.
Discussion
The AhR plays important physiological roles in many cells of
the immune system, notably the Th17 subset of CD4 T cells
[9,10,26,31]. Most of the current literature on AhR effects in the
immune system is focused on the consequences of exposure to the
high affinity ligand TCDD. However, many recent studies of mice
lacking AhR expression indicate that AhR activation affects
important physiological functions in the absence of xenobiotic
ligands [32]. There is a range of potential physiological ligands for
AhR [33,34] including diet-derived AhR ligands which strongly
influence intestinal immune parameters [35]. A current contro-
versy in the field is the apparent ligand-specific influence on the
outcome of experimental models of autoimmunity such as EAE.
The current paradigm is that TCDD promotes immune suppres-
sion, whereas endogenous ligands such as FICZ promote Th17
cell responses and thereby pathology [9]. However, in our view it
seems more likely that the mode of application of a ligand rather
than its nature defines the outcome. Thus, systemic administration
of AhR ligands, affecting a multitude of tissues and cells types,
appears to cause strong reduction of the concurrently induced
immune response even in the case of FICZ, without the
involvement of numerical changes or induction of Treg. In
contrast, local injection of FICZ, which was incorporated into the
antigen emulsion for induction of EAE seemed to more directly
target and promote developing Th17 cells, thereby exacerbating
pathology in EAE [10].
We decided to revisit the issue of ligand dependent effects of
AhR looking at in vitro and in vivo Th17 cell responses in the
presence of either TCDD or the endogenous ligand FICZ or other
reported AhR ligands. It was clear that TCDD did not have
differential effects compared to other AhR ligands during in vitro
differentiation of Th17 cells and their induction of IL-22,
suggesting that there is no intrinsically different mode of action
distinguishing TCDD from other ligands. Affinity measurements
for AhR polymorphisms have been conducted with respect to
binding of TCDD in a hepatocyte cell line, and it is not clear at
present whether other AhR ligands bind at the same location. This
is an important issue as humans seem to express AhR of an affinity
that is closer to that of AhRd than AhRb [36]. Affinity differences
in AhR influenced the amounts of IL-17 and IL-22 protein that
were produced by in vitro differentiated Th17 cells with signifi-
cantly lower amounts secreted by cells from AhRd mice. However,
there was no difference in susceptibility to EAE between mice
expressing AhR of low or high affinity. As this disease is strongly
dependent on Th17 cells [11,37], it appears that the number of
Th17 cells in mice with low affinity AhR and the amounts of IL-17
protein produced are nevertheless sufficient to initiate disease.
It remains to be elucidated whether functional responses of
other AhR expressing immune cell types are more or less affected
by the affinity of AhR.
In contrast to its effect on in vitro Th17 cell differentiation,
TCDD strongly suppressed Th17 cell development and the
induction of EAE as described previously, a phenomenon that
has been associated with the induction of Treg (reviewed in [38]).
Similarly the suppression of EAE by another proposed endogenous
ligand 2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid meth-
yl ester (ITE) was suggested to be due to the induction of Treg
[17]. As all of the publications invoking induction of Treg by the
Figure 2. Administration of TCDD after initiation of the
immune response does not result in immunosuppression. A)
Clinical scores of mice immunized with MOG/CFA which received either
vehicle (filled circles) or TCDD i.p. at the time of immunization (open
circles) or 7 days after immunization (open squares). Table showing
incidence, mean day of onset and mean maximum score of disease.
Data shown as mean 6 SEM are representative of 2 experiments, ****
p,0.0001, two-way ANOVA followed by Dunnet post-test. B) Number
of Foxp3+ and of IL-17A+ T cells recovered at day 9 after immunization
from draining lymph nodes of immunized mice who received vehicle,
TCDD on day 0 or TCDD on day 7 after immunization; n = 4. Data shown
as mean6 SEM are representative of 2 experiments, *p,0.05, **p,0.01
in one-way ANOVA followed by Dunnet post-test.
doi:10.1371/journal.pone.0079819.g002
AhR Effects on Th17 Responses
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AhR ligand TCDD demonstrate alterations in frequencies rather
than absolute numbers, alternative interpretations for the apparent
increase in Treg may apply. For instance, Treg cells are more
resistant to apoptosis than conventional T cells [39,40], surviving
interventions that kill other T cells [41–43], which might result in
alterations of relative frequencies. Given that AhR has long been
known to interfere with regular cell cycle progression and that
TCDD can induce cell cycle arrest [44], it is possible that T cell
population dynamics are altered in the presence of TCDD with
significant impact for the progression of immune responses. It
should be noted that there was no obvious effect of TCDD on cell
proliferation during Th17 cell differentiation in vitro. However, this
does not necessarily rule out effects of TCDD on cell dynamics in
vivo. We found no evidence for an induction of Foxp3 during
exposure of naı¨ve T cells to TCDD and TCDD did not influence
the TGFb mediated generation of iTreg in vitro. In addition we did
not observe a numerical increase in Treg during induction of EAE
despite an increase in frequency that has been reported previously.
We therefore think it unlikely that the suppressive effect of TCDD
manifests itself through the induction of Treg. This interpretation
is furthermore supported by data in the literature that found no
Figure 3. AhR activation by TCDD and FICZ in vitro promotes Th17 but not Foxp3+ Treg cells. A) Left panel: ahr expression from in vitro
differentiated Th0, Th17 and Treg cells, and ex vivo sorted natural Th17 (nTh17) and Treg cells (nTreg) Data shown as mean6 SEM are representative
of 2 experiments; n = 2–4. Right panel: cyp1a1 expression from in vitro differentiated Th0 or Th17 in the presence or absence of FICZ. Data shown as
mean 6 SEM are representative of 2 experiments; n = 3. B) Fold increase of foxp3 expression in cultured naı¨ve T cells activated in the presence of
TCDD, FICZ or TGFb over control conditions without mediators at the indicated timepoint. C) Representative FACS dot plots showing Foxp3 staining
of sorted naı¨ve T cells activated in the presence of indicated ligands and cytokines. D) Representative FACS dot plots showing IL-17A and IL-22
staining in naı¨ve T cell activated in the presence of IL-6 and TGFb, plus the depicted AhR ligands. E) Representative histogram showing proliferation
of in vitro differentiated Th17 cells (gated on IL-17+ cells) in the presence or absence of TCDD by CTV dilution; table shows the average division index
(average number of cell divisions each cell has undergone), replication index (fold-expansion of dividing cells) and percentage of divided cells for
each group, and the corresponding p value from Student’s T test analysis. F) Representative FACS dot plots showing IL-17A and Foxp3 staining in
naı¨ve T cell co-cultured with bone marrow derived DC in the presence of the indicated cytokines and ligands. Data are representative of 2
independent experiments.
doi:10.1371/journal.pone.0079819.g003
Figure 4. AhR positively controls IL-1 receptor type 1 on Th17 cells. A) Naı¨ve CD4+ T cells from WT B6 (black bars) and AhR2/2 mice (white
bars) were differentiated into Th0, Th1, Th2, iTreg, and Th17 cells for 3 days and the relative gene expression of Il-1r1 was determined by quantitative
RT-PCR. B) Il-1r1 expression of WT Th17 cells cultured with (filled circles) or without FICZ (open circles) and AhR2/2 Th17 cells (open squares) was
assessed at 18, 24, and 48h after the onset of Th17 differentiation. C) Th17 cells were induced from naı¨ve WT CD4+ T or AhR2/2 naı¨ve CD4+ T cells for
3 days and the expression level of surface IL-1R1 was analyzed gated on IL-17-producing cells. Data are representative of at least two independent
experiments.
doi:10.1371/journal.pone.0079819.g004
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evidence of increased Treg in mice with constitutively active AhR
[45].
Furthermore, it appears that while all AhR ligands tested
similarly affected in vitro Th17 function, the endogenous
ligand FICZ proved to exert substantial suppression of EAE
responsiveness - albeit lower than that by TCDD - if administered
systemically by peritoneal injection. This indicates that AhR
mediated effects on different cell types are integrated in the final
response in vivo. AhR signalling seems to be tightly controlled
under physiological conditions via induction of the downstream
Figure 6. Restricting AhR deficiency to either T cells or dendritic cells partially abrogates TCDDmediated suppression of EAE. A) ahr
mRNA expression in FACS sorted CD4 T cells from AhRfl/+ or AhRfl/2 Rag1.Cre mice. B) Clinical score of mice with Rag1-specific AhR-deletion (open
circles, open triangles) or control mice immunized with MOG/CFA (filled circles, filled triangles) which received either vehicle (circles) or TCDD
(triangles) i.p. at the time of immunization. n = 6–8, ** p,0.01 in two-way ANOVA followed by Dunnet post-test. C) Table showing incidence, mean
day of onset and mean maximum score of disease for both experimental groups; n = 6-8, data shown as mean 6 SEM. D) ahr expression in FACS
sorted CD11c+ MHCII+ cells from AhRfl/+ or AhRfl/2 CD11c.Cre mice. E) Clinical score of mice with CD11c-specific AhR-deletion (open circles or open
triangles) or control mice (filled circles, filled triangles) immunized with MOG/CFA which received either vehicle (circles) or TCDD (triangles) i.p. at the
time of immunization. F) Table showing incidence, mean day of onset and mean maximum score of disease for both experimental groups; n = 9–11,
data shown as mean 6 SEM, * p,0.05 in two-way ANOVA followed by Dunnet post-test.
doi:10.1371/journal.pone.0079819.g006
Figure 5. ahrb1 and ahrd carrying mice show similar in vitro Th17 differentiation and in vivo disease kinetics following MOG-CFA
immunization. A) Frequency of IL-17A (left panel) and IL-22 (right panel) -expressing cells following culture of naı¨ve CD4+ T cells in Th17-promoting
conditions in the presence of different AhR ligands for 4 days; cells bear either the ahrb1 (black bars) or the ahrd (grey bars) allele for AhR. n = 3–4, data
shown as mean 6 SEM are representative of 2 independent experiments. B) mRNA expression of il17a (left panel) and il22 (right panel) in Th17 cells
cultured in the presence of different AhR ligands for 4 days; cells bear either the ahrb1 (black bars) or the ahrd (grey bars) allele for AhR. n = 3–4, data
shown as mean 6 SEM are representative of 2 independent experiments. *** p,0.001 in a two-way ANOVA test. C) Quantification of IL-17A (left
panel) and IL-22 (right panel) protein levels in supernatant obtained from Th17 cells cultured in the presence of different AhR ligands for 4 days; cells
bear either the ahrb1 (black bars) or the ahrd (grey bars) allele for AhR. n = 3–5, data shown as mean 6 SEM are representative of 2 independent
experiments. *** p,0.001 in a two-way ANOVA test. D) Clinical score of mice bearing either ahrb1 (closed circles) or the ahrd (open circles) allele for
AhR, immunized with CFA emulsified with MOG peptide. n = 8 mice per group.
doi:10.1371/journal.pone.0079819.g005
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CYP450 family members CYP1A1, CYP1A2 and CYP1B1 that
metabolise endogenous ligands, thereby curtailing AhR signalling
[20]. Additional feedback controls via induction of the AhRR [46]
as well as proteasomic degradation of AhR are in place to control
AhR activity [47]. Prolonged signalling occurs following admin-
istration of TCDD, which cannot be metabolised, and it was
suggested that this might underlie dysregulated responses in the
presence of TCDD [48,49].
Given that AhR is expressed widely in the immune system and
also on epithelial and stromal cells, that under in vivo conditions
will interact and influence immune cells, we have attempted to
restrict responsiveness to AhR by analysing mice with cell type
specific deletion of AhR for their susceptibility to EAE. Neither the
absence of AhR in CD11c expressing antigen-presenting cells, nor
in Rag1 expressing immune cells influenced the induction and the
course of EAE. However, restricting AhR deficiency to either cell
type partly abolished the suppressive effect of TCDD. This
suggests that both antigen presenting cells as well as T cells are
targets for TCDD, so that suppression of either component will
result in a degree of disease amelioration. It is known that
immunoregulatory features such as the production of IDO by
antigen presenting cells is enhanced by AhR stimulation [50,51]
and the kynurenine pathway also was suggested to influence IL-10
production by dendritic cells [16]. We observed for instance that
dendritic cells isolated from draining lymph nodes of mice
immunized for induction of EAE together with systemic applica-
tion of FICZ showed considerably higher expression of IL-10
(Fig. S1). Taken together our data suggest that AhR ligands
exert complex influences on many cell types, including
antigen-presenting cells and T cells, which during EAE are
integrated in downstream Th17-mediated immune sequelae.
Furthermore, time as well as route of administration led to distinct
outcomes of Th17 dependent immune responses. More studies are
needed to elucidate on the molecular level what the effects of this
transcription factor are on different immune cell types (as well as
epithelial and stromal cells) that participate in the generation of
beneficial as well as pathogenic immune responses in vivo.
Supporting Information
Figure S1 Dendritic cells from mice immunized simul-
taneously with systemic AhR stimulation express in-
creased levels of IL-10. A) CD11c+ cells were sorted from
either draining lymph nodes (dLN) or spleen (spl) at day 12 after
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